Imugene Ltd (ASX:IMU, OTC:IUGNF) is gearing up to present two of its innovative therapeutic platforms to some of the world’s most prestigious clinicians, researchers, patient advocates, journalists and industry representatives at the European Society for Medical Oncology (ESMO) Congress.
The biotech stock’s B cell immunotherapy, HER-Vaxx, and its CF33 oncolytic virotherapy, CHECKVacc, will take centre stage at the major oncology event in Madrid from October 20 to October 24.
Imugene will feature in two poster sessions at the ESMO symposium; the first presented by Dr Joshua Tobias from the Medical University of Vienna and the second facilitated by Dr Jamie Rand from the City of Hope.
Dr Tobias will discuss a Phase 2 study of HER-Vaxx, where Imugene used a HER2-targeting peptide vaccine plus standard of care chemotherapy in patients with HER2+ advanced stomach cancer.
In essence, the poster session will present findings that indicate dose-dependent anti-cancer antibodies correlated with an improved clinical outcome.
Meanwhile, Dr Rand will outline the induction of an inflammatory tumour microenvironment, achieved using an oncolytic virus CF33-hNIS-antiPD-L1 intratumoral injection in patients with metastatic triple-negative breast cancer.
Beyond the symposium, Imugene is committed to developing new cancer therapies and improving the lives of the millions of patients who need effective treatments.
Together with leading specialists and medical professionals, the company believes its immuno-oncology therapies will become foundational treatments for cancer.